| Study |
Reference |
|
Anderka, 2012
|
Anderka M Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol 2012;94:22-30
|
|
Andersen, 2013
|
Andersen JT Ondansetron use in early pregnancy and the risk of congenital malformations – a registry based nationwide cohort study Abstract. Pharmacoepidemiol Drug Saf. 2013;22(Suppl 1):13–14
|
|
Bérard, 2019
|
Bérard New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. J Clin Epidemiol 2019; 116:39-48
|
|
Clements, 2015
|
Clements CC Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry 2015;20:727-34
|
|
Colvin, 2013
|
Colvin L Off-label use of ondansetron in pregnancy in Western Australia. Biomed Res Int 2013;2013:909860
|
|
Danielsson, 2014
|
Danielsson B Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol 2014;50:134-7
|
|
Einarson (Control exposed to other antiemetics), 2004
|
Einarson A The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004;111:940-3
|
|
Einarson (Unexposed control), 2004
|
Einarson A The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004;111:940-3
|
|
Fejzo, 2015
|
Fejzo MS Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol 2015;189:79-84
|
|
Fejzo (Mainly exposed to other treatements, sick), 2016
|
Fejzo MS Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol 2016;62:87-91
|
|
Fejzo (Unexposed control, disease free), 2016
|
Fejzo MS Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol 2016;62:87-91
|
|
Huybrechts, 2019
|
Huybrechts Intravenous Ondansetron in Pregnancy
and Risk of Congenital Malformations JAMA Published online November 15, 2019
|
|
Huybrechts (Control exposed to other treatment), 2018
|
Huybrechts KF Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA 2018;320:2429-2437
|
|
Huybrechts (Unexposed control), 2018
|
Huybrechts KF Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA 2018;320:2429-2437
|
|
Kerr, 2018
|
Kerr Risk factors for congenital microcephaly in the pre-Zika era. Birth Defects Res 2019; 111:96-118
|
|
Lemon, 2019
|
Lemon Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. Int J Epidemiol 2019; :
|
|
Lind, 2013
|
Lind Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007. Pharmacoepidemiol Drug Saf 2013; 22:783-93
|
|
Marciniak, 2015
|
Marciniak A The influence of intravenous ondansetron on maternal blood haemodynamics after spinal anaesthesia for caesarean section: a double-blind, placebo-controlled study. Ginekol Pol 2015;86:461-7
|
|
Oofuvong, 2018
|
Oofuvong Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial. BMC Anesthesiol 2018; 18:105
|
|
Ozdemirci, 2014
|
Ozdemirci S The Safety of Ondansetron and Chlorpromazine for Hyperemesis Gravidarum in First Trimester Pregnancy Gynecol Obstet Reprod Med 2014;20:81-84
|
|
Parker, BDS study, 2018
|
Parker SE Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. Obstet Gynecol 2018;132:385-394
|
|
Parker, NBDPS study, 2018
|
Parker SE Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. Obstet Gynecol 2018;132:385-394
|
|
Pasternak, 2013
|
Pasternak B Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med 2013;368:814-23
|
|
Shahraki, 2016
|
Shahraki Comparing Neonatal Outcome Following the Use of Ondansetron versus Vitamin B6 in Pregnant Females with Morning Sickness: A Randomized Clinical Trial J Compr Ped. 2016;7(4):e37081.
|
|
Werler, 2014
|
Werler Medication use in pregnancy in relation to the risk of isolated clubfoot in offspring. Am. J. Epidemiol. 2014; 180:86-93
|
|
Zambelli-Weiner (Unexposed control, NOS), 2019
|
Zambelli-Weiner A First trimester ondansetron exposure and risk of structural birth defects. Reprod Toxicol 2019;83:14-20
|
|
Zambelli-Weiner (Unexposed control, sick), 2019
|
Zambelli-Weiner A First trimester ondansetron exposure and risk of structural birth defects. Reprod Toxicol 2019;83:14-20
|
